Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout DUBLIN, Ireland, June 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...

Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993 MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...